Group Pharmaceuticals
Specialist oral-care pharma maker (Malur, Karnataka) earning ~₹14 Cr pre-tax a year, quoted at ₹55 per ₹10 share.
Market cap
₹69.85 Cr
1.27 Cr shares
P/E ratio
6.72
Sector average 28
Book value
₹59.61
P/B 0.92
1-year return
+0.00%
52w ₹55 – ₹55
Currently 0% of the way through its 52-week range.
Indicative price history
1Y change
+0.00% ₹55 → ₹55
52-week band in this window: ₹55.00 – ₹55.00. Weekly indicative marks, not exchange-traded prices.
Key highlights
- Niche oral-care pharma with two WHO-GMP plants at Malur, Karnataka.
- PBT ₹13.5 Cr (FY24) and ₹13.9 Cr (FY25); cash generative.
- Dealer quote ₹55 implies ~₹70 Cr market value on 1.27 Cr shares.
About Group Pharma
Group Pharmaceuticals Ltd was incorporated in July 1980 and is registered at Tarapur MIDC, Thane, with its main operations at two WHO-GMP plants in Malur, 43 km from Bengaluru, built out from 2002. It develops and manufactures niche oral-care products — medicated toothpastes, gels, mouthwashes, syrups and creams — for specific dental and oral conditions, marketed to dentists and through pharmacies, plus contract manufacturing for other brands.
Financial summaries show profit before tax of ₹13.52 Cr in FY24 and ₹13.88 Cr in FY25, with operating cash flow of ₹10.04 Cr and ₹9.53 Cr respectively. Registry records give paid-up capital of ₹12.7 Cr (authorised ₹25 Cr) — about 1.27 Cr shares of ₹10 — though an older record shows ₹2.54 Cr, suggesting a bonus issue in between.
wwipl.com quotes ₹55 (0% change). On 1.27 Cr shares that is a market value near ₹70 Cr, or roughly 7x estimated FY25 earnings.
Figures preliminary; verify from MCA filings. Revenue and balance-sheet lines are estimates around the disclosed pre-tax profit and cash flow.
Where the revenue comes from
- Own oral-care brands70%
Medicated toothpastes, gels, mouthwashes marketed to dentists
- Contract manufacturing25%
Toothpaste, syrups and creams for third-party brands
- Other5%
Exports and miscellaneous
Products & services
Medicated toothpastes and gels
Dentist-prescribed products for sensitivity, gum disease and oral lesions
Mouthwashes and syrups
Antiseptic rinses and oral liquids
Contract manufacturing
Toothpaste, creams and syrups for third-party brands
What works
- • Dominant niche in dentist-prescribed oral care with brands built over two decades.
- • Consistent profitability: PBT ₹13.5–13.9 Cr and ₹9.5–10 Cr of operating cash flow in each of FY24 and FY25.
- • Low valuation — about 7x earnings if the share count is confirmed.
What to watch
- • Profit has plateaued (₹13.5 Cr → ₹13.9 Cr PBT); growth in the niche is slow.
- • Share-count records conflict (₹2.54 Cr vs ₹12.7 Cr paid-up); per-share metrics change 5x depending on which is right.
- • Competition from large FMCG oral-care brands entering medicated segments.
- • Dealer quote unchanged over observed periods — very low liquidity.
Compare with peers
| Company | Price | Market cap | P/E | P/B | Rev CAGR |
|---|---|---|---|---|---|
| Group PharmaThis page | ₹55.00 | ₹69.85 Cr | 6.72 | 0.92 | +6.90% |
| Martin & Harris | ₹959.00 | ₹479.5 Cr | 11.99 | 1.88 | +9.92% |
| Pharmed | ₹820.00 | ₹353.11 Cr | 4.37 | 1.19 | +13.55% |
Latest reported year: FY25 ending 31 Mar 2025.